Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections
Authors' conclusion
AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.
Study context
- Population
- Youth aged 13–25 years with T1D and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI)all completed
- Participants
- 20 participants
- Exposure
- Advanced hybrid closed loop (AHCL) after transition from MDI
- AHCLn = 20
- Outcome
- Glycemic outcomes
- Follow-up
- 3 months
Methodological detailsdual-center, 3-month
- Dual-center
- 3-month
Main finding
As reported in the abstract
HbA1c, baseline → 3 months (mean ± SD)
10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) → 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol)
TIR 70-180 mg/dL (3.9-10.0 mmol/L), baseline → 3 months
27.6 ± 13.2% → 66.5 ± 9.8%
Observational data: associations, not effects.
Safety
- DKA episodes attributed to infusion set failure
- 2
Original publication
Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections. Diabetes Care. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →